Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Xenotransplantation of pre-pubertal ovarian cortex and prevention of follicle depletion with anti-Müllerian hormone (AMH).

Detti L, Fletcher NM, Saed GM, Sweatman TW, Uhlmann RA, Pappo A, Peregrin-Alvarez I.

J Assist Reprod Genet. 2018 Oct;35(10):1831-1841. doi: 10.1007/s10815-018-1260-z. Epub 2018 Jul 25.

2.

The distribution, clearance, and safety of an anti-MMP-9 DNAzyme in normal and MMTV-PyMT transgenic mice.

Hallett MA, Dalal P, Sweatman TW, Pourmotabbed T.

Nucleic Acid Ther. 2013 Dec;23(6):379-88. doi: 10.1089/nat.2012.0348. Epub 2013 Oct 1.

3.

Synthesis and photochemical transformation of 3β,21-dihydroxypregna-5,7-dien-20-one to novel secosteroids that show anti-melanoma activity.

Zmijewski MA, Li W, Chen J, Kim TK, Zjawiony JK, Sweatman TW, Miller DD, Slominski AT.

Steroids. 2011 Jan;76(1-2):193-203. doi: 10.1016/j.steroids.2010.10.009. Epub 2010 Nov 9.

4.

The melatonin-producing system is fully functional in retinal pigment epithelium (ARPE-19).

Zmijewski MA, Sweatman TW, Slominski AT.

Mol Cell Endocrinol. 2009 Aug 13;307(1-2):211-6. doi: 10.1016/j.mce.2009.04.010. Epub 2009 May 3.

5.

Synthesis and photo-conversion of androsta- and pregna-5,7-dienes to vitamin D3-like derivatives.

Zmijewski MA, Li W, Zjawiony JK, Sweatman TW, Chen J, Miller DD, Slominski AT.

Photochem Photobiol Sci. 2008 Dec;7(12):1570-6. doi: 10.1039/b809005j. Epub 2008 Sep 4.

6.

Photo-conversion of two epimers (20R and 20S) of pregna-5,7-diene-3beta, 17alpha, 20-triol and their bioactivity in melanoma cells.

Zmijewski MA, Li W, Zjawiony JK, Sweatman TW, Chen J, Miller DD, Slominski AT.

Steroids. 2009 Feb;74(2):218-28. doi: 10.1016/j.steroids.2008.10.017. Epub 2008 Nov 6.

7.

20-Hydroxyvitamin D3, a product of vitamin D3 hydroxylation by cytochrome P450scc, stimulates keratinocyte differentiation.

Zbytek B, Janjetovic Z, Tuckey RC, Zmijewski MA, Sweatman TW, Jones E, Nguyen MN, Slominski AT.

J Invest Dermatol. 2008 Sep;128(9):2271-80. doi: 10.1038/jid.2008.62. Epub 2008 Mar 27.

8.

N-Benzyladriamycin-14-valerate (AD 198): a non-cardiotoxic anthracycline that is cardioprotective through PKC-epsilon activation.

Hofmann PA, Israel M, Koseki Y, Laskin J, Gray J, Janik A, Sweatman TW, Lothstein L.

J Pharmacol Exp Ther. 2007 Nov;323(2):658-64. Epub 2007 Aug 10.

PMID:
17693586
9.
10.

A comparison of 3 routes of flumazenil administration to reverse benzodiazepine-induced desaturation in an animal model.

Unkel JH, Brickhouse TH, Sweatman TW, Scarbecz M, Tompkins WP, Eslinger CS.

Pediatr Dent. 2006 Jul-Aug;28(4):357-62.

PMID:
16903446
11.

Oncostatic effects of the indole melatonin and expression of its cytosolic and nuclear receptors in cultured human melanoma cell lines.

Fischer TW, Zmijewski MA, Zbytek B, Sweatman TW, Slominski RM, Wortsman J, Slominski A.

Int J Oncol. 2006 Sep;29(3):665-72.

PMID:
16865283
12.

Constitutive and UV-induced metabolism of melatonin in keratinocytes and cell-free systems.

Fischer TW, Sweatman TW, Semak I, Sayre RM, Wortsman J, Slominski A.

FASEB J. 2006 Jul;20(9):1564-6. Epub 2006 Jun 22. Erratum in: FASEB J. 2007 Feb;21(2):630.

PMID:
16793870
14.

Melatonin increases survival of HaCaT keratinocytes by suppressing UV-induced apoptosis.

Fischer TW, Zbytek B, Sayre RM, Apostolov EO, Basnakian AG, Sweatman TW, Wortsman J, Elsner P, Slominski A.

J Pineal Res. 2006 Jan;40(1):18-26.

PMID:
16313494
15.

Rhodamine-123: therapy for hormone refractory prostate cancer, a phase I clinical trial.

Jones LW, Narayan KS, Shapiro CE, Sweatman TW.

J Chemother. 2005 Aug;17(4):435-40.

PMID:
16167524
16.

Chemical compatibility of depacon(®) with medications frequently administered by intravenous y-site delivery in patients with epilepsy or head trauma.

Rashed SM, Sweatman TW, Thoma L, Hovinga CA, Phelps SJ.

J Pediatr Pharmacol Ther. 2004 Apr;9(2):126-32. doi: 10.5863/1551-6776-9.2.126.

17.

Circumvention of nuclear factor kappaB-induced chemoresistance by cytoplasmic-targeted anthracyclines.

Bilyeu JD, Panta GR, Cavin LG, Barrett CM, Turner EJ, Sweatman TW, Israel M, Lothstein L, Arsura M.

Mol Pharmacol. 2004 Apr;65(4):1038-47.

PMID:
15044634
18.
19.
20.

Novel extranuclear-targeted anthracyclines override the antiapoptotic functions of Bcl-2 and target protein kinase C pathways to induce apoptosis.

Barrett CM, Lewis FL, Roaten JB, Sweatman TW, Israel M, Cleveland JL, Lothstein L.

Mol Cancer Ther. 2002 May;1(7):469-81.

21.

Anthracycline drug targeting: cytoplasmic versus nuclear--a fork in the road.

Lothstein L, Israel M, Sweatman TW.

Drug Resist Updat. 2001 Jun;4(3):169-77. Review.

PMID:
11768330
22.

Molecular models of N-benzyladriamycin-14-valerate (AD 198) in complex with the phorbol ester-binding C1b domain of protein kinase C-delta.

Roaten JB, Kazanietz MG, Sweatman TW, Lothstein L, Israel M, Parrill AL.

J Med Chem. 2001 Mar 29;44(7):1028-34.

PMID:
11297449
23.

Comparative pharmacokinetics of submucosal vs. intravenous flumazenil (Romazicon) in an animal model.

Oliver FM, Sweatman TW, Unkel JH, Kahn MA, Randolph MM, Arheart KL, Mandrell TD.

Pediatr Dent. 2000 Nov-Dec;22(6):489-93.

PMID:
11132509
24.

Rationale for intralesional valrubicin in chemoradiation of squamous cell carcinoma of the head and neck.

Wani MK, Koseki Y, Yarber RH, Sweatman TW, Ahmed A, Samant S, Hengesteg A, Israel M, Robbins KT.

Laryngoscope. 2000 Dec;110(12):2026-32.

PMID:
11129014
25.

Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288).

Lothstein L, Suttle DP, Roaten JB, Koseki Y, Israel M, Sweatman TW.

Biochem Pharmacol. 2000 Dec 1;60(11):1621-8.

PMID:
11077044
26.

Pharmacology of N-benzyladriamycin-14-valerate in the rat.

Sweatman TW, Seshadri R, Israel M.

Cancer Chemother Pharmacol. 1999;43(5):419-26.

PMID:
10100599
28.
29.

Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat.

Han G, Israel M, Seshadri R, Dalton JT, Sweatman TW.

Cancer Chemother Pharmacol. 1996;37(5):472-8.

PMID:
8599871
30.
31.
32.
34.

Pharmacologic rationale for intravesical N-trifluoroacetyladriamycin-14-valerate (AD 32): a preclinical study.

Sweatman TW, Parker RF, Israel M.

Cancer Chemother Pharmacol. 1991;28(1):1-6.

PMID:
2040028
35.

Inhibition of mitochondrial carnitine palmitoyltransferases by adriamycin and adriamycin analogues.

Kashfi K, Israel M, Sweatman TW, Seshadri R, Cook GA.

Biochem Pharmacol. 1990 Oct 1;40(7):1441-8.

PMID:
2222502
36.

Metabolism and elimination of rhodamine 123 in the rat.

Sweatman TW, Seshadri R, Israel M.

Cancer Chemother Pharmacol. 1990;27(3):205-10.

PMID:
2265456
38.

Clinical pharmacology of continuous infusion doxorubicin.

Sweatman TW, Lokich JJ, Israel M.

Ther Drug Monit. 1989;11(1):3-9.

PMID:
2911850
39.

Comparative uptake and retention of adriamycin and N-benzyladriamycin-14-valerate in human CEM leukemic lymphocyte cell cultures.

Israel M, Sweatman TW, Seshadri R, Koseki Y.

Cancer Chemother Pharmacol. 1989;25(3):177-83.

PMID:
2598408
40.

Amelioration of adriamycin toxicity through modification of drug-DNA binding properties.

Israel M, Seshadri R, Koseki Y, Sweatman TW, Idriss JM.

Cancer Treat Rev. 1987 Dec;14(3-4):163-7. No abstract available.

PMID:
3440247
41.

Comparative metabolism and elimination of adriamycin and 4'-epiadriamycin in the rat.

Sweatman TW, Israel M.

Cancer Chemother Pharmacol. 1987;19(3):201-6.

PMID:
3472675
42.

Metabolic activation of N-acylanthracyclines precedes their interaction with DNA topoisomerase II.

Silber R, Liu LF, Israel M, Bodley AL, Hsiang YH, Kirschenbaum S, Sweatman TW, Seshadri R, Potmesil M.

NCI Monogr. 1987;(4):111-5.

PMID:
3041237
43.

A brief evaluation of cardiac gated MRI in left ventricular ejection fraction determinations: a comparison with standard left ventriculography DSA and nuclear medicine.

Le Page R, Crandall CR, Hood CH, Enerson RD, Schrepel J, Sweatman TW, Fleetwood DJ.

Ann Radiol (Paris). 1986;29(2):87-90. No abstract available.

PMID:
3740747
44.

The role of the gut flora in the reduction of sulphinpyrazone in the rat.

Renwick AG, Evans SP, Sweatman TW, Cumberland J, George CF.

Biochem Pharmacol. 1982 Aug 15;31(16):2649-56.

PMID:
7138558
45.

Tissue levels of saccharin in the rat during two-generation feeding studies.

Sweatman TW, Renwick AG.

Toxicol Appl Pharmacol. 1982 Mar 15;62(3):465-73. No abstract available.

PMID:
7071861
46.

The pharmacokinetics of saccharin in man.

Sweatman TW, Renwick AG, Burgess CD.

Xenobiotica. 1981 Aug;11(8):531-40.

PMID:
7303723
47.

The tissue distribution and pharmacokinetics of saccharin in the rat.

Sweatman TW, Renwick AG.

Toxicol Appl Pharmacol. 1980 Aug;55(1):18-31. No abstract available.

PMID:
7191585
48.

Saccharin metabolism and tumorigenicity.

Sweatman TW, Renwick AG.

Science. 1979 Sep 7;205(4410):1019-20.

PMID:
472722
49.

The absorption of saccharin from the rat urinary bladder.

Renwick AG, Sweatman TW.

J Pharm Pharmacol. 1979 Sep;31(9):650-2. No abstract available.

PMID:
41079

Supplemental Content

Loading ...
Support Center